



ORIGINAL ARTICLE

Vitamin D status and risk of infections after liver transplantation in the Swiss Transplant Cohort Study

Peter W. Schreiber¹, Heike A. Bischoff-Ferrari², Katia Boggian³, Christian van Delden⁴, Natalia Enriquez⁴, Thomas Fehr⁵ , Christian Garzoni⁶, Hans H. Hirsch⁷, Cédric Hirzel⁶, Oriol Manuel^{8,9}, Pascal Meylan⁸, Lanja Saleh¹⁰, Maja Weisser⁷, Nicolas J. Mueller¹ , the Swiss Transplant Cohort Study (STCS)*

1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

2 Department of Geriatrics and Aging Research, University Hospital Zurich, Zurich, Switzerland

3 Division of Infectious Diseases and Hospital Hygiene, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

4 Service of Transplantation, Department of Surgery, University Hospitals Geneva, University of Geneva, Geneva, Switzerland

5 Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland

6 Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

7 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland

8 Infectious Diseases Service, University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland

9 Transplantation Center, University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland

10 Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland

SUMMARY

Increasing evidence indicates a role of vitamin D in the immune system affecting response to infections. We aimed to characterize the role of vitamin D status, i.e. deficiency [25-OH vitamin D (25-OHD) <50 nmol/l] and no deficiency (25-OHD ≥50 nmol/l) in incident infections after liver transplantation. In 135 liver transplant recipients, blood samples drawn at time of liver transplantation and 6 months afterwards were used to determine 25-OHD levels. Incident infections episodes were prospectively collected within the Swiss Transplant Cohort Study database. Poisson regression was applied to address associations between vitamin D status and incident infections. Vitamin D deficiency was common at time of transplantation and 6 months afterwards without a significant change in median 25-OHD levels. In univariable analyses, vitamin D deficiency was a risk factor for incident infections in the first 6 months post-transplant incidence rate ratio (IRR 1.52, 95% CI 1.08–2.15, $P = 0.018$) and for bacterial infections occurring after 6 up to 30 months post-transplant (IRR 2.29, 95% CI 1.06–4.94, $P = 0.034$). These associations were not detectable in multivariable analysis with adjustment for multiple confounders. Efforts to optimize vitamin D supplementation in liver transplant recipients are needed. Our data question the role of vitamin D deficiency in incident infections.

Transplant International 2019; 32: 49–58

Key words

infections, liver transplantation, post-transplant care, vitamin D

Received: 21 March 2018; Revision requested: 18 April 2018; Accepted: 3 August 2018;

Published online: 3 September 2018

Correspondence

Nicolas J. Mueller MD, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.

Tel.: +41 44 255 3712;

fax: +41 44 255 3291;

e-mail: nicolas.mueller@usz.ch

ClinicalTrials.gov number: NCT01204944.

*See Appendix 1 section for list of the members of the Swiss Transplant Cohort.

Introduction

Vitamin D deficiency is highly prevalent in patients with end-stage organ failure including patients listed for organ transplantation [1–3]. The majority of vitamin D is synthesized in the skin via ultraviolet light exposure, only a small proportion is ingested by food intake. 25-position hydroxylation of vitamin D takes place in the liver forming 25-OH vitamin D (25-OHD) which is used as an indicator of vitamin D status [4]. In the kidneys, an additional 1-position hydroxylation is performed resulting in the biologically active form 1, 25-(OH)₂ vitamin D [4].

Besides its well-established role for bone metabolism, vitamin D has been linked to infections [5], cardiovascular diseases, and overall survival [6,7] in the general population. In chronic liver disease, vitamin D deficiency has been associated with the degree of liver dysfunction [8], infections [9], and even mortality [8,9]. Some data suggest an influence of vitamin D on infections in solid organ transplant recipients [10,11]. Beyond assessment of the vitamin D status at time of transplantation and 6 months after transplantation, our study specifically addressed the question whether vitamin D deficiency is associated with incident infections in liver graft recipients. We divided a total observation period of 2.5 years into two periods, the first 6 months after transplantation and 6 months post-transplant until 2.5 years post-transplant. Our analysis took the vitamin D status at time of transplantation and at 6 months post-transplant for the first period and the second period into account, respectively.

Patients and methods

Study design, population, and patient-related data

This study was performed within the Swiss Transplant Cohort Study (STCS, www.stcs.ch, ClinicalTrials.gov number: NCT01204944). The STCS prospectively collects data and biosamples from all six transplant centers in Switzerland (i.e. Basel, Bern, Geneva, St. Gallen, Lausanne and Zurich). Since May 2008, all solid organ transplants have been registered within the STCS database, for data analysis and sampling an informed consent is obtained. Enrollment is >93% of all transplantations in Switzerland [12]. The STCS was approved by the Ethic Committees of all participating institutions. Liver transplantations of enrolled participants were performed between May 2008 and July 2011. Enrollment included liver transplant recipients within the STCS, available plasma samples and

ongoing informed consent at the follow-up of 2.5 years after transplantation. With the exception of information about vitamin D supplementation, which was retrospectively added by patient chart review, all other data were prospectively collected. Dedicated professionals supervised by transplant infectious diseases physicians prospectively record infections every 6 months in the first year post-transplant and afterwards every year. For analysis of the association between vitamin D levels and infections, only clinically relevant infections, i.e. symptomatic and, if possible, resulting in targeted treatment, were considered. Clinical presentations interpreted suggestive of an infectious etiology and prompting initiation of antimicrobial treatment by the treating physicians were rated as probable infections, if routine diagnostics remained without identification of a pathogen. For the subgroup analysis of bacterial infections, we defined proven bacterial infections as clinically apparent infections combined with detection of the causative bacterium and initiation of targeted antimicrobial treatment.

Laboratory analysis

For laboratory analyses, prospectively collected blood samples of the participating transplant recipients were retrieved from the STCS biobank. Blood samples drawn at the time of transplant and samples obtained 6 months post-transplant were used for centralized, uniform measurement at the Institute of Clinical Chemistry of the University Hospital Zurich. 25-OH vitamin D measurement was performed with Roche Diagnostics Vitamin D total assay on Cobas[®] 8000 (Roche Diagnostics, Mannheim, Germany).

Vitamin D status was categorized as deficiency, if 25-OH vitamin D <50 nmol/l (20 ng/ml), whereas 25-OH vitamin D levels ≥50 nmol/l were considered as no deficiency.

Statistical analysis

All statistical analyses were performed with R (version 3.3.2). Continuous variables were reported as median and interquartile range (IQR), categorical variables as absolute numbers, and frequencies (%). Statistical testing was performed with two-sided tests, *P*-values <0.05 were considered significant. Wilcoxon rank-sum test was used for comparison of continuous variables between two groups, whereas Wilcoxon matched-pairs signed-rank test was applied for pairwise comparisons. Multiple group comparison was performed with Kruskal–Wallis test. Linear relationships were assessed by Pearson correlation. Categorical variables were

compared using Fisher's Exact test. For investigation of the association between vitamin D levels and incident infections, we defined two observation periods. The first period referred to the timespan from transplantation to 6 months post-transplant, for this analysis vitamin D values measured at time of transplantation were considered. The second period comprised the timespan beginning after 6 months post-transplant until 30 months post-transplant, for this period, 25-OH vitamin D values determined at 6 months after transplantation were taken into account. For analysis regarding defined time periods, patients with shorter follow-up either because of death or lost to follow-up were excluded (five out of 135 liver recipients for an observation period up to 30 months). Poisson regression was applied to identify risk factors associated with infections. In the univariable analysis, we tested the variables age, sex, type of graft (whole versus split), vitamin D status (no deficiency versus deficiency), use of induction immunosuppression, body mass index (BMI), and self-reported mobility. In addition, model of end-stage liver disease (MELD) and Child-Pugh score were added exclusively for the analysis on vitamin D levels peritransplant and incident infections within the first 6 months after transplantation, as prior research highlighted relevance of these parameters in cirrhotic patients as well as in the early post-transplant period [13,14]. If number of events was sufficient, all these variables were taken into the multivariable model with the exception of variables showing collinearity. For the analysis of the association between vitamin D levels and incident proven bacterial infections after 6 up to 30 months after transplantation, we decided to limit our multivariable analysis on five independent variables with respect to the number of events ($n = 49$) to avoid over-adjustment. The present model was chosen under consideration of best fit and the prerequisite of inclusion of vitamin D levels. Vitamin D supplementation at time transplant and 6 months after transplantation was intentionally not considered in analysis, as we addressed the associations with vitamin D levels itself and not the presence of supplementation therapy.

Results

Patients' characteristics

Of the 135 participants, 64.4% were males, 132 (97.8%) were Caucasian. Median age of liver recipients was 54 years (IQR 45–61) (Table 1). The most common reasons for liver transplantation were hepatitis C

Table 1. Baseline characteristics.

Variable	
Age (median (IQR))	54 years (45–61)
Sex (n , %)	Male 87 (64.4%) Female 48 (35.6%)
Ethnicity (n , %)	Caucasian 132 (97.8%) Asian 2 (1.5%) African 1 (0.7%)
Underlying disease (n , %)	Hepatitis C 30 (22.2%) Alcohol abuse 28 (20.7%) Hepatocellular carcinoma 22 (16.3%) Hepatitis B 15 (11.1%) Extrahepatic biliary atresia 5 (3.7%) Primary biliary cirrhosis 5 (3.7%) Extrahepatic biliary atresia 5 (3.7%) Cholangiocarcinoma 4 (3.0%) Primary sclerosing cholangitis 4 (3.0%) Other 17 (12.6%)
MELD (median (IQR))	20 (14–28)
Child-Pugh stage* (n , %)	A 44 (32.6%) B 42 (31.1%) C 29 (21.5%)
Hepatorenal syndrome (n , %)	Present, no RRT 18 (13.3%) Present, RRT 12 (8.8%) Absent, no RRT 98 (72.6%) Unknown 7 (5.2%)
Type of donation (n , %)	Deceased donor: DBD 126 (93.3%) Living donor: Living related 6 (4.4%) Living unrelated 3 (2.2%)
Type of transplant (n , %)	Whole liver 121 (89.7%) Split liver 14 (10.4%)
Induction therapy (n , %)	Basiliximab 89 (65.9%)† Rituximab 1 (0.7%) None 45 (33.3%)
Maintenance immunosuppression‡ (n , %)	Tac + MMF + steroids 17 (12.6%) Tac + MMF 24 (17.8%) Tac solely 17 (12.6%) CsA + MMF + steroids 8 (5.9%) CsA + MMF 20 (14.8%) CsA solely 7 (5.2%) MMF + steroids 4 (3.0%) Other regimen 38 (28.1%)
Vitamin D supplementation (n , %)	Peritransplant§: Cholecalciferol 24 (17.8%) 1, 25-dihydroxycholecalciferol 2 (1.5%) None 108 (80.0%) 6 months post-transplant¶: Cholecalciferol 55 (40.7%) 1, 25-dihydroxycholecalciferol 2 (1.5%) None 70 (51.9%)

CsA, cyclosporine A; DBD, donation after brain death; EC-MPA, enteric-coated mycophenolate; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; RRT, renal replacement therapy; Tac, tacrolimus.

*Data for 20 participants missing.

†One combined with glucocorticoids, one combined with rituximab.

‡At 6 months post-transplant.

§Data for one participant missing.

¶Data for eight participants missing.

($n = 30$, 22.2%), alcohol abuse ($n = 28$, 20.7%), hepatitis B ($n = 15$, 11.1%), or incidence of hepatocellular carcinoma ($n = 22$, 16.3%). One hundred and twenty-six (93.3%) grafts derived from deceased donors, six (4.4%) from living related donors, and three (2.2%) from a living unrelated donor. At time of transplantation, median model of end-stage liver disease (MELD) score was 20 (IQR 14–28). Induction immunosuppression was administered in 90 (66.7%) participants. Peritransplant 24 (17.8%) participants received cholecalciferol (median dose 800 IU) and two (1.5%) participants 1, 25-dihydroxycholecalciferol (median dose 0.25 μg). Six months post-transplant 55 (40.7%) liver recipients obtained supplementation with cholecalciferol (median dose 800 IU) and two (1.5%) participants with 1, 25-dihydroxycholecalciferol (median dose 0.125 μg).

Vitamin D status

Peritransplant, the majority of liver transplant recipients showed a deficiency of 25-OHD ($n = 96$, 71.1%). In 39 (28.9%) individuals, 25-OHD levels of at least 50 nmol/l were detected. Six months post-transplant 88 (66.2%) patients had vitamin D deficiency. No vitamin D deficiency was present in 45 (33.8%) individuals (Fig. 1). 25-OHD measured peritransplant (median 32.5 nmol/l, IQR 12.6–55.8 nmol/l) and 6 months post-transplant (median 35.4 nmol/l, IQR 19.7–62.7 nmol/l) did not significantly differ ($P = 0.067$). At transplantation, 88.0% of liver recipients without vitamin D supplementation showed 25-OHD values <50 nmol/l (vs. 50.0% of recipients

treated with vitamin D analogues). Six months after transplantation, 50.0% of liver recipients with supplementation therapy and 77.5% without supplementation were vitamin D-deficient (25-OHD <50 nmol/l).

Vitamin D status and infections

Infections within the first 6 months post-transplant of liver recipients

Overall 190 infections affecting 94 participants occurred within the first 6 months after liver transplantation: 98 (51.6%) bacterial, 41 (21.6%) viral, 6 (3.2%) fungal infections, 1 (0.5%) parasitic infection, and 44 (23.2%) suspected infections prompting antimicrobial treatment, in which identification of the causative pathogen was not successful (Fig. 2). The most common, by bacterial infections affected sites were the gastrointestinal tract ($n = 40$, 40.8%), bacteremia ($n = 22$, 22.5%), urinary tract ($n = 13$, 13.3%), and respiratory tract ($n = 5$, 5.1%) (Fig. 3).

Univariable Poisson regression showed an increased risk of infection for administration of induction immunosuppression (IRR 1.48, 95% CI 1.07–2.05; $P = 0.019$), higher MELD (IRR 1.04, 95% CI 1.02–1.06; $P < 0.001$) or Child-Pugh score (IRR 1.08, 95% CI 1.01–1.16; $P = 0.017$), and vitamin D deficiency (IRR 1.52, 95% CI 1.08–2.15; $P = 0.018$) (Table 2). No association with incident infections were found for age, sex, type of liver graft, BMI, and self-reported mobility at time of transplantation. With regard to collinearity between MELD and Child-Pugh score, only MELD




Figure 1 Distribution of 25-OH vitamin D values of liver transplant recipients peritransplant and 6 months post-transplant.




Figure 2 Infections occurring in the first 6 months after transplantation and more than 6 up to 30 months post-transplant.

Bacterial infections first 6 months post-transplant

Bacterial infections after 6 up to 30 months post-transplant




Figure 3 Site of infection in bacterial infections after liver transplantation.

score was added to the multivariable model ($r = 0.435$, $P < 0.001$). In multivariable analysis, higher MELD score (IRR 1.03, 95% CI 1.01–1.05; $P = 0.003$) correlated positively with risk of incident infections, whereas male sex was protective (IRR 0.67, 95% CI 0.45–0.98; $P = 0.040$). No significant association with vitamin D levels was detected.

Restricting Poisson regression to bacterial infections identified a positive correlation with increasing MELD (univariable IRR 1.05, 95% CI 1.03–1.07; $P < 0.001$), Child-Pugh score (univariable IRR 1.17, 95% CI 1.06–1.28; $P = 0.001$) as well as higher BMI (univariable IRR 1.04, 95% CI 1.00–1.08; $P = 0.037$) (Table 3). In a multivariable model, male sex was associated with a lower risk of incident infections (IRR 0.52, 95% CI 0.30–0.91; $P = 0.021$), but none of the additionally investigated variables, including vitamin D levels at time of transplantation, showed a significant association.

Infections after 6 up to 30 months after liver transplantation

A total of 158 infections affecting 68 individuals were recorded in this observation period, composed of 49 (31.0%) bacterial infections, 24 (15.2%) viral infections, 4 (2.5%) fungal infections, and 81 (51.3%) infections without identification of the causative pathogen (Fig. 2). Bacterial infections most frequently were bacteremia ($n = 13$, 26.5%) or affected the gastrointestinal tract ($n = 9$, 18.4%), respiratory tract ($n = 8$, 16.3%) or the skin and mucous membranes ($n = 8$, 16.3%) (Fig. 3).

In univariable analysis increasing age protected from infections (IRR per decade 0.83, 95% CI 0.76–0.92; $P < 0.001$), whereas vitamin D status, sex, type of liver graft, use of induction immunosuppression, BMI at 6 months post-transplant, and self-reported mobility 6 months after transplantation did not show a significant association with incident infections. Multivariable analysis

Table 2. Poisson regression analysis of risk for infections within the first 6 months post-transplant and after 6 up to 30 months post-transplant.

	First 6 months post-transplant			After 6 up to 30 months post-transplant		
	Univariable analysis		Multivariable analysis	Univariable analysis		Multivariable analysis
	Incidence rate ratio (95% CI)	P	Incidence rate ratio (95% CI)	Incidence rate ratio (95% CI)	P	Incidence rate ratio (95% CI)
Vitamin D status*						
No deficiency	Reference		Reference	Reference		Reference
Deficiency	1.52 (1.08–2.15)	0.018	1.19 (0.79–1.81)	1.15 (0.81–1.64)	0.430	1.19 (0.75–1.91)
Age						
Per decade increase	0.99 (0.90–1.09)	0.875	0.93 (0.79–1.08)	0.83 (0.76–0.92)	<0.001	0.93 (0.77–1.14)
Sex						
Female	Reference		Reference	Reference		Reference
Male	0.79 (0.59–1.06)	0.114	0.67 (0.45–0.98)	1.36 (0.95–1.96)	0.094	1.19 (0.75–1.89)
MELD score†						
Per point increase	1.04 (1.02–1.06)	<0.001	1.03 (1.01–1.05)			
Child-Pugh score‡						
Per point increase	1.08 (1.01–1.16)	0.017				
Type of graft						
Whole liver	Reference		Reference	Reference		Reference
Split liver	1.02 (0.64–1.62)	0.944	1.31 (0.64–2.70)	1.56 (0.97–2.50)	0.065	1.15 (0.54–2.45)
Induction immunosuppression						
None	Reference		Reference	Reference		Reference
Any	1.48 (1.07–2.05)	0.019	1.53 (1.00–2.34)	1.23 (0.86–1.76)	0.262	0.89 (0.56–1.41)
BMI*						
Per point increase	1.02 (0.99–1.05)	0.204	1.01 (0.97–1.05)	0.98 (0.94–1.01)	0.218	1.03 (0.97–1.08)
Mobility*						
No problems	Reference		Reference	Reference		Reference
Some problems	1.00 (0.71–1.42)	0.996	0.84 (0.58–1.20)	1.16 (0.77–1.76)	0.474	1.07 (0.68–1.69)
Confined to bed	2.04 (0.82–5.04)	0.125	1.25 (0.48–3.25)	3.16 (1.00–10.04)	0.051	3.62 (1.01–12.90)

MELD, model of end-stage liver disease.

* Assessment at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and after 6 up to 30 months post-transplant, respectively.

† At time of transplantation.

Table 3. Poisson regression analysis of risk for bacterial infections within the first 6 months post-transplant and after 6 up to 30 months post-transplant.

	First 6 months post-transplant			After 6 up to 30 months post-transplant		
	Univariable analysis		Multivariable analysis	Univariable analysis		Multivariable analysis
	Incidence rate ratio (95% CI)	P	Incidence rate ratio (95% CI)	P	Incidence rate ratio (95% CI)	P
Vitamin D status*	Reference		Reference		Reference	
No deficiency	1.49 (0.92–2.41)	0.106	0.96 (0.54–1.70)	0.879	2.29 (1.06–4.94)	0.034
Deficiency					Reference	Reference
Age					1.09 (0.45–2.66)	0.844
Per decade increase	1.00 (0.88–1.15)	0.973	0.99 (0.78–1.25)	0.901	0.84 (0.70–1.00)	0.049
Sex					0.79 (0.56–1.11)	0.170
Female	Reference		Reference		Reference	
Male	0.80 (0.53–1.20)	0.278	0.52 (0.30–0.91)	0.021	3.34 (1.41–7.92)	0.006
MELD score†					2.99 (1.17–7.63)	0.022
Per point increase	1.05 (1.03–1.07)	<0.001	1.02 (0.99–1.06)	0.131		
Child-Pugh score†						
Per point increase	1.17 (1.06–1.28)	0.001				
Type of graft						
Whole liver	Reference		Reference		Reference	
Split liver	1.32 (0.74–2.37)	0.349	1.20 (0.41–3.52)	0.741	0.47 (0.11–1.95)	0.299
Induction immunosuppression						
None	Reference		Reference		Reference	
Any	1.46 (0.93–2.30)	0.103	1.48 (0.78–2.81)	0.227	1.17 (0.61–2.24)	0.641
BMI*						
Per point increase	1.04 (1.00–1.08)	0.037	1.03 (0.96–1.10)	0.403	0.96 (0.89–1.03)	0.228
Mobility*						
No problems	Reference		Reference		Reference	
Some problems	0.91 (0.55–1.51)	0.711	0.73 (0.43–1.23)	0.239	1.54 (0.73–3.23)	0.256
Confined to bed	0.84 (0.12–6.12)	0.862	0.49 (0.06–3.77)	0.493	4.05 (0.54–30.27)	0.173
						0.248
						0.267

MELD, model of end-stage liver disease.

* Assessment at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and after 6 up to 30 months post-transplant, respectively.

† At time of transplantation.

identified increased risk of incident infections in transplant recipient reporting major limitations in self-reported mobility 6 months after transplantation (IRR 3.62, 95% CI 1.01–12.90; $P = 0.047$), solely.

Focusing exclusively on bacterial infections, vitamin D deficiency (IRR 2.29, 95% CI 1.06–4.94; $P = 0.034$) and male sex (IRR 3.34, 95% CI 1.41–7.92; $P = 0.006$) increased risk of incident infections, but increasing age (IRR 0.84, 95% CI 0.70–1.00; $P = 0.049$) was protective in univariable analysis (Table 3). Multivariable analysis only confirmed the positive correlation between male sex and incident infections (IRR 2.99, 95% CI 1.17–7.63; $P = 0.022$). Notably, vitamin D status (IRR 1.09, 95% CI 0.45–2.66; $P = 0.844$) lost its association after adjustment.

Discussion

In our study, vitamin D status of liver allograft recipients was determined by uniform, centralized measurement utilizing prospectively collected samples gathered at the time of transplantation and 6 months post-transplant. Vitamin D deficiency was highly prevalent at both time points, transplantation and 6 months post-transplant. In longitudinal measurements, no significant change in 25-OHD levels was observed in liver graft recipients. Multivariable analyses did not confirm an association of vitamin D levels with incident infections or proven bacterial infections.

In chronic liver disease, vitamin D deficiency is common [9]. Several reasons may contribute to persisting vitamin D deficiency after transplantation. Physicians might have prescribed an insufficient dose of vitamin D, which could be aggravated by an increased demand (compared to nontransplant patients) to reach normal vitamin D levels. Recent reports indicated that an initial loading dose is beneficial to replenish vitamin D levels [15]. Notably, none of our patients received a loading dose. Furthermore, transplant patients are instructed to avoid sun exposure, because of the increased risk of skin cancer due to immunosuppression, which results in omission of the most important vitamin D source. This hypothesis is also supported by the absence of a seasonal influence on 25-OHD 6 months post-transplant (Table S1). In our opinion, malcompliance with prescribed supplementation therapy seems unlikely, but there was no assessment for compliance with supplementation therapy. Approaches to improve vitamin D supplementation therapy might benefit from a better knowledge of pharmacokinetics in transplant recipients [16,17].

Several studies support a link between vitamin D and antimicrobial effects; an impact on both innate and adaptive immunity is postulated. 1, 25-(OH)₂ vitamin D can be produced by monocytes and macrophages via

CYP27B1-hydroxylase using 25-OHD as necessary substrate. The produced 1, 25-(OH)₂ vitamin D activates vitamin D receptor-directed genes such as cathelicidin and results in killing of the ingested pathogen [18,19]. The active form of cathelicidin, LL-37, has been shown to be able to disrupt bacterial membranes and viral envelopes [20]. This mechanism seems not to be limited to monocytes and macrophages. Increasing evidence is present for barriers like skin [21], gut [22] and lung [23] being capable of using this pathway. This pathway might be hampered if an insufficient amount of 25-OHD is available. In cirrhotic patients, a positive correlation between vitamin D deficiency and incident infections has been reported previously [9,24]. In the present study, univariable analyses showed an association of vitamin D deficiency and incident infections within the first 6 months (first observation period) and bacterial infections after 6 up to 30 months post-transplant. However, multivariable analyses could not confirm these associations indicating that adjustment for confounders vanished the observation.

A limitation of our study is the retrospective assessment of vitamin D supplementation. The strengths include serial 25-OHD measurement with uniform methods, the prospective study design and the availability of follow-up data up to 2.5 years post-transplant for almost all study participants.

In conclusion, our study challenges the postulated role of vitamin D in infections after liver transplantation, as this association got lost after adjustment for multiple confounders. Despite supplementation therapy, a relevant proportion of our patients were deficient or severely deficient, a finding in need of action.

Authorship

PWS: designed research/study, performed research/study, collected data, analyzed data, wrote the paper. HBF: designed research/study, performed research/study, critically reviewed manuscript. KB: performed research/study, collected data, critically reviewed manuscript. CvD: performed research/study, collected data, critically reviewed manuscript. NE: performed research/study, collected data, critically reviewed manuscript. TF: designed research/study, performed research/study, collected data, critically reviewed manuscript. CG: performed research/study, collected data, critically reviewed manuscript. HHH: performed research/study, collected data, critically reviewed manuscript. CH: performed research/study, collected data, critically reviewed manuscript. OM: performed research/study, collected data, critically reviewed manuscript. PM: performed research/study, collected data, critically reviewed manuscript. LS: performed

research/study, performed laboratory measurements, critically reviewed manuscript. MW: performed research/study, collected data, critically reviewed manuscript. NJM: designed research/study, performed research/study, collected data, analyzed data, wrote the paper.

Funding

This study has been conducted in the framework of the Swiss Transplant Cohort Study, supported by the Swiss National Science Foundation, the Swiss University Hospitals (G15) and Transplant Centers.

Conflict of interest

The authors have declared no conflicts of interest.

Acknowledgements

The authors thank all patients for their willingness to participate in the STCS. Alex Marzel, Mohaned Shilaih, and Alexandra Scherrer are acknowledged for their support in data analysis and critical comments.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. 25-OH vitamin D values peritransplant and 6 months post-transplant by season.

REFERENCES

1. Tschopp O, Boehler A, Speich R, *et al.* Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. *Am J Transplant* 2002; **2**: 167.
2. Monegal A, Navasa M, Peris P, *et al.* Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades? *Calcif Tissue Int* 2013; **93**: 571.
3. Sadlier DM, Magee CC. Prevalence of 25 (OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. *Clin Transplant* 2007; **21**: 683.
4. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol* 2009; **19**: 73.
5. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2009; **169**: 384.
6. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med* 2008; **168**: 1629.
7. Dobnig H, Pilz S, Scharnagl H, *et al.* Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med* 2008; **168**: 1340.
8. Putz-Bankuti C, Pilz S, Stojakovic T, *et al.* Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. *Liver Int* 2012; **32**: 845.
9. Finkelmeier F, Kronenberger B, Zeuzem S, Piiper A, Waidmann O. Low 25-hydroxyvitamin D levels are associated with infections and mortality in patients with cirrhosis. *PLoS ONE* 2015; **10**: e0132119.
10. Kwon YE, Kim H, Oh HJ, *et al.* Vitamin D deficiency is an independent risk factor for urinary tract infections after renal transplants. *Medicine* 2015; **94**: e594.
11. Lowery EM, Bemiss B, Cascino T, *et al.* Low vitamin D levels are associated with increased rejection and infections after lung transplantation. *J Heart Lung Transplant* 2012; **31**: 700.
12. Koller MT, van Delden C, Muller NJ, *et al.* Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. *Eur J Epidemiol* 2013; **28**: 347.
13. Abad CL, Lahr BD, Razonable RR. Epidemiology and risk factors for infection after living donor liver transplantation. *Liver Transplant* 2017; **23**: 465.
14. Tandon P, Abraldes JG, Keough A, *et al.* Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. *Clin Gastroenterol Hepatol* 2015; **13**: 1189.e2.
15. Chaney A, Heckman MG, Diehl NN, Meek S, Keaveny AP. Effectiveness and outcomes of current practice in treating vitamin d deficiency in patients listed for liver transplantation. *Endocr Pract* 2015; **21**: 761.
16. Benaboud S, Urien S, Thervet E, *et al.* Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. *Eur J Clin Pharmacol* 2013; **69**: 499.
17. Courbebaisse M, Alberti C, Colas S, *et al.* VITamin D supplementation in renal transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. *Trials* 2014; **15**: 430.
18. Adams JS, Hewison M. Update in vitamin D. *J Clin Endocrinol Metab* 2010; **95**: 471.
19. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against *Mycobacterium tuberculosis* is dependent on the induction of cathelicidin. *J Immunol* 2007; **179**: 2060.
20. Braff MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. *Curr Top Microbiol Immunol* 2006; **306**: 91.
21. Frohm Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. *Infect Immun* 1999; **67**: 2561.

22. Liu N, Nguyen L, Chun RF, *et al.* Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. *Endocrinology* 2008; **149**: 4799.
23. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. *J Immunol* 2008; **181**: 7090.
24. Buonomo AR, Zappulo E, Scotto R, *et al.* Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. *Int J Infect Dis* 2017; **63**: 23.

APPENDIX 1

The members of the Swiss Transplant Cohort Study are: Patrizia Amico, John-David Aubert, Vanessa Banz, Guido Beldi, Christian Benden, Christoph Berger, Isabelle Binet, Pierre-Yves Bochud, Elsa Boëly, Heiner Bucher, Thierry Carell, Emmanuelle Catana, Yves Chalandon, Sabina de Geest, Olivier de Rougemont, Michael Dickenmann, Michel Duchosal, Laure Elkrief, Thomas Fehr, Sylvie Ferrari-Lacraz, Christian Garzoni, Paola Gasche Socal, Christophe Gaudet, Emiliano Giostra, Déla Golshayan, Karine Hadaya, Jörg Halter, Dominik Heim, Christoph Hess, Sven Hillinger, Hans H. Hirsch, Günther Hofbauer, Uyen Huynh-Do, Franz Immer, Richard Klaghofer, Michael Koller (Head of the data center), Bettina Laesser, Roger Lehmann, Christian Lovis, Pietro Majno; Oriol Manuel, Hans-

Peter Marti, Pierre Yves Martin, Pascal Meylan, (Head, Biological samples management group), Paul Mohacsi, Philippe Morel, Ulrike Mueller, Nicolas J Mueller (Chairman Scientific Committee), Helen Mueller-McKenna (Head of local data management), Antonia Müller, Thomas Müller, Beat Müllhaupt, Manuel Pascual (Executive office), Jakob Passweg, Klara Posfay-Barbe, Juliane Rick, Eddy Roosnek, Anne Rosselet, Silvia Rothlin, Frank Ruschitzka, Urs Schanz, Stefan Schaub, Aurelia Schnyder, Christian Seiler, Jan Sprachta; Susanne Stampf, Jürg Steiger (Head, Executive Office), Guido Stirnimann, Christian Toso, Christian Van Delden (Executive office), Jean-Pierre Venetz, Jean Villard, Madeleine Wick (STCS coordinator), Markus Wilhelm, Patrick Yerly.